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Background: Stenotrophomonas maltophilia is an important opportunistic, mainly nosocomial pathogen that
emerged in the last decades worldwide. Due to its inherent extended antibiotic resistance, therapeutic options are
strongly limited. New resistance mechanisms in S. maltophilia make antibiotic therapy even more difficult. The aim
of our study was to investigate the antimicrobial resistance of S. maltophilia isolates collected in our laboratory and
to reveal related clinical background.
Method: Consecutive non-duplicate S. maltophilia isolates (n = 160) were collected in a three-year period.
Conventional methods, automated identification system and MALDI-TOF MS was used for identification, ERIC-PCR
for genetic relationship analysis and broth microdilution method to determine the susceptibility for trimethoprim/
sulfamethoxazole (SXT), ciprofloxacin, levofloxacin, moxifloxacin, colistin, doxycycline and tigecycline. Clinical final
reports were used retrospectively to collect clinical information.
Results: ERIC-PCR revealed large heterogeneity. Trimethoprim/sulfamethoxazole, moxifloxacin and levofloxacin were
found to be the most effective agents with MIC50/MIC90 0.5/1, 0.25/1, 1/2 mg/l, respectively. Seventy percent of
patients with S. maltophilia infection were treated in intensive care units. All-cause mortality rate was 45%. Nearly 70%
of the isolates were collected from polymicrobial infections/colonizations.
Conclusions: Trimethoprim/sulfamethoxazole is the most potent antibiotic agent against S. maltophilia. In case of SXT
hypersensitivity, intolerance or resistance, fluoroquinolones are alternative therapeutic options. Missing clinical
breakpoints, consensus antibiotic susceptibility testing guidelines and clinical trials make the interpretation of antibiotic
susceptibility testing results difficult. The indirect pathogenicity of S. maltophilia in polymicrobial infections or
colonizations has to be taken into consideration.
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Stenotrophomonas maltophilia has emerged as an im-
portant opportunistic and nosocomial pathogen in recent
years worldwide [1,2]. Behind Pseudomonas aeruginosa and
Acinetobacter baumannii, S. maltophilia is the third most
common non-fermenting Gram-negative bacillus respon-
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unless otherwise stated.acquired S. maltophilia infections have also been reported
[3]. Pneumonia and bacteraemia are the most frequent in-
fections [1,2]. Due to its inherent extended antibiotic resist-
ance, therapeutic options are strongly limited [1,2,4].
Currently only trimethoprim/sulfamethoxazole (SXT) is
recommended for therapy, but some circumstances
(hypersensitivity of the patient, resistance of the bacter-
ium) can limit the use of this drug [1,2]. In such cases,
susceptibility of S. maltophilia isolates for other anti-
microbials must be tested, even if clinical evidences for
their efficacy are lacking yet [4]. Increasing number ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tients, patients undergoing long-term intensive care, etc.),
the necessity of the usage of broad-spectrum antibiotics
such as carbapenems (which cause selective pressure for
the inherently carbapenem-resistant S. maltophilia) and
the natural features of this bacterium (biofilm forming
ability, colonizing moist hospital environments) together
mean that S. maltophilia is a continuous threat we have to
face [1,2,5]. The high attributable mortality rates and poor
outcomes reported in S. maltophilia infection makes the
spread of this bacterium even more worrisome [6]. The
emergence of new resistance mechanisms in S. maltophilia
requires substantial monitoring and reporting of antibiotic
suspectibility of clinical isolates [5].
The aim of our study was to investigate the anti-
microbial resistance of S. maltophilia isolates collected in
Diagnostic Laboratory of Clinical Microbiology, Institute of
Laboratory Medicine, Semmelweis University (Budapest,
Hungary) and to reveal whether isolates were infective or
colonizers, the type of infections, the predisposing factors
of infected patients, antibiotic therapy and the outcome of
infections.
Materials and methods
A total of 160 consecutive non-duplicate S. maltophilia
isolates from a three-year collection period (2009–2011)
were investigated in our study. The identification of the
isolates was performed with conventional methods,
VITEK 2 Gram-negative identification cards (bioMérieux,
Marcy l’Etoile) and additionally by MALDI-TOF mass
spectrometry (Bruker Daltonics, Bremen). For MALDI-
TOF MS identification, the direct smear and 1 μL alpha-
Cyano-4-hydroxycinnamic acid matrix overlay method
was applied [7]. Parameters of the device were set accord-
ing to the recommendation of Bruker. Identifications were
assigned using the Bruker Biotyper 2.0 software. Bioty-
per score ≥2.0 were accepted as valid species level
identification. Identification results as “Stenotropho-
monas maltophilia”, “Stenotrophomonas maltophilia
(Pseudomonas beteli)”, “Stenotrophomonas maltophilia
(Pseudomonas hibiscicola)” were all accepted. Pseudo-
monas hibiscicola and P. beteli are belonging to Steno-
trophomonas rRNA lineage [8].
The isolates were divided into two groups: isolates of
patients who were infected by S. maltophilia and of
those who were colonized only. Infection or colonization
was distinguished according to clinical diagnoses given
in final reports. Selected cases were discussed with phys-
ician to reveal clinical relevance of isolates. The defini-
tive diagnosis of infection was clinically established.
Colonization was defined as the presence of S. maltophi-
lia on skin, mucous membranes, in wounds, or in excre-
tions or secretions without causing adverse clinical signs
or symptoms. Isolates of infected patients (n = 100) werecultured from blood (n = 25), bronchoalveolar lavage sam-
ple (n = 30), tracheal aspirate (n = 31), sputum (n = 7),
central venous catheter (n = 4), peritoneal fluid (n = 3).
Isolates of colonized patients (n = 60) were cultured from rec-
tal swab (n = 11), urine (n = 8), ear swab (n = 6), throat - (n =
3), nose - (n = 4), eye swab (n = 7), catheter (n = 1), sputum
(n =7), tracheal aspirate (n = 7) and wound sample (n = 6).
The minimal inhibitory concentrations (MICs) of seven
antibiotics were determined by the reference broth micro-
dilution method in cation-adjusted Mueller-Hinton broth
[9]. MIC values of the invasive isolates were tested by agar
dilution method and by gradient diffusion test, too [9-11].
The antibiotics tested included SXT (0.25-128 mg/L), cip-
rofloxacin (0.5-256 mg/L), moxifloxacin (0.064-32 mg/L),
levofloxacin (0.064-32 mg/L), colistin (0.25-256 mg/L),
doxycycline (0.064-32 mg/L) and tigecycline (0.064-
32 mg/L). The European Committee on Antimicrobial
Susceptibility Testing (EUCAST) has S. maltophilia
specific clinical breakpoint only for SXT [12]. Therefore,
non-species related breakpoints of EUCAST were applied
for fluoroquinolons and tigecycline. For doxycyline – due
to absence of non-species related breakpoints – the
epidemiological cut-off (ECOFF) value of S. maltophilia
(8 mg/L) was applied. For colistin – lacking non-species
related break-points and approved ECOFF - Pseudomonas
sp. specific breakpoint (4 mg/L) was used. Escherichia coli
ATCC 25922, Pseudomonas aeruginosa ATCC 27853 and
Staphylococcus aureus ATCC 29213 were used as quality
control strains.
Enterobacterial Repetitive Intergenic Consensus PCR
(ERIC-PCR) was used for molecular typing of isolates, as
described by Silbert et al. [13]. Isolates from the same
ward were tested within the same PCR amplification and
gel electrophoreses run. Band patterns obtained by
ERIC-PCR were visually evaluated in the absence of
appropriate software. Isolates with two or more different
bands were interpreted as unrelated.
Clinical data and laboratory findings (white blood cell
number (WBC), C-reactive protein (CRP) and procalci-
tonin (PCT)) of patients at the time of S. maltophilia in-
fections were collected retrospectively from clinical final
reports. Details of antibiotic therapy used in S. maltophi-
lia infections were investigated.
Patient characteristics were tested for their association
with overall mortality. First, univariate analysis using
chi-squere test or Fisher exact test was performed. A p-
value of <0.05 was considered as significant. Variables
with significant association with mortality in the univari-
ate analysis were entered in a multivariate forward step-
wise logistic regression model to identify independent
risk factors for death. The odds ratio (OR) with the cor-
responding 95% confidence interval (95% CI) for each
variables were calculated. A p-value of <0.05 was con-
sidered indicative of statistical significance. Stata 12
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tical analysis.
Results
Biotyper 2.0 softver of Bruker MALDI-TOF MS classified
77% of the isolates as S. maltophilia, 16% as S. maltophilia
(P. hibiscicola) and 7% as S. maltophilia (P. beteli).
ERIC-PCR resulted in highly diverse patterns, however
seven identical patterns among colonizer (4 times 2 iso-
lates and 3 times 3 isolates with the same band patterns)
and twelve among infective isolates (6 times 2 isolates, 4
times 3 isolates and once 5 isolates and once 6 isolates
with the same band patterns) were found. In order to
prevent the distortion of values by clonal isolates, 10
colonizer and 23 infective isolates were excluded from
the final evaluation of antibiotic susceptibility testing
results.
The results obtained with microdilution, gradient dif-
fusion and agar dilution methods were in concordance.
However, results obtained with agar dilution - especially
in case of SXT - were difficult to evaluate due to slight
growth of microcolonies at adjacent antibiotic concen-
trations. The MIC50 and MIC90 values, MIC ranges and
susceptibility in % of selected isolates with different
ERIC-PCR patterns were summarized in Table 1. How-
ever, MIC values did not differ significantly if the total of
100 infective and 60 colonizer isolates were evaluated.
The susceptibility rates of infective and colonizer S. mal-
tophilia isolates were compared. Both groups showed high




MIC range MIC 50
SXT S ≤ 4, R > 4 infective <0.25- > 32 0.25
colonizer <0.25- > 32 0.5
ciprofloxacin S ≤ 0.5 , R > 1 infective <0.5-64 2
colonizer 0.5-128 2
levofloxacin S≤ 1 , R > 2 infective 0.125-16 1
colonizer <0.064-4 0.5
moxifloxacin S≤ 0.5 , R > 1 infective <0.064-8 0.25
colonizer <0.064-4 0.125
doxycycline** infective 0.125-4 1
colonizer 0.125-4 1
tigecycline S≤ 0.25, R > 0.5 infective 0.125-16 0.5
colonizer 0.125-16 0.5
colistin S≤ 4, R > 4 infective 1- > 256 64
colonizer 0.25- > 128 16
Number of infective isolates = 77
Number of colonizer isolates = 50
*Breakpoints according to EUCAST. TMP-SMX breakpoints are specific for S. maltoph
Colistin breakpoints are Pseudomonas sp. specific.
**ECOFF of doxycycline of S. maltophilia is 8 mg/l.infective isolates had higher rates of non-susceptibility
than had colonizers. Non-susceptibility rate for colistin
and tigecycline were 1.2-1.3 times higher in the infective
group.
The analysis of clinical background of 100 infective
isolates revealed that 70% were cultured from patients
admitted to intensive care units (ICU). Sixty-two isolates
were obtained from patients with pneumonia (12 of
them developing respiratory failure). Forty-six patients
had sepsis (23 of them developing severe sepsis, septic
shock or multiorgan failure), in 19 cases S. maltophilia
was considered as the ethiological agent. The co-
morbidity was chronic obstructive pulmonary disease
(COPD) in 19 cases and malignancy in 19 cases, respect-
ively. Nine patients were immunsuppressed (3 of them
had lung transplantation). Clinical data and their correl-
ation with mortality are shown in Table 2. The all-cause
mortality was 45%. In 25% of fatal cases S. maltophilia
was regarded to have direct role in death. Twenty pa-
tients have not received specific antimicrobial therapy
for S. maltophilia (13 of them died); however, patients
received antibiotics against co-infective bacteria. In 11
cases colistin was applied, 9 of them were fatal. Twenty-
nine patients were treated with SXT, 7 of them died. Six
patients were treated with ciprofloxacin (5 died), 17 with
moxifloxacin (3 died), 16 with levofloxacin (7 died), one
with tigecycline (1 died).
The mortality was significantly associated with the fol-
lowing variables: ICU admission, need for mechanical
ventilation, vasopressor therapy, presence of multiorgan% of isolates
MIC 90 Resistant Intermediate Susceptible
1 1 0 99
1 2 0 98
8 54 22 24
8 76 12 12
2 7 18 75
2 4 12 84
1 7 6 87
0.5 4 6 90
2 Insufficient evidence
2
2 50 38 12
2 14 51 35
>256 91 0 9
>128 77 0 23
ilia. Fuoroquinolone and tigecycline breakpoints are non-species related.






No (%) No (%)
Age in years, median (range) 67 (0–88) 62 (0–88) -
Gender, male 23 (51.1) 35 (63.6) 0.29
Hematological malignancy 3 (6.6) 3 (5.4) 0.31
Advanced cancer 10 (22.2) 8 (14.5) 0.54
Diabetes mellitus 16 (35.5) 16 (29.1) 0.22
Corticosteroid use 4 (8.8) 8 (14.5) 0.31
Chemotherapy 4 (8.8) 11 (20) 0.2
Neutropenia (<0.5 G/L) 5 (11.1) 2 (3.6) 0.24
Post-transplantation stage 0 5 (9.1) -
Chronic heart disease 15 (33.3) 18 (32.7) 0.88
Chronic kidney disease, hemodialysis 10 (22.2) 5 (9.1) 0.12
Chronic lung disease 13 (28.8) 14 (25.4) 0.87
Chronic liver disease 5 (11.1) 7 (12.7) 0.95
Hypertension 30 (66.6) 25 (45.4) 0.05
Admission to intensive care unit 43 (95.5) 32 (58.2) 0.00005
Need for vasopressors 26 (57.7) 8 (14.5) 0.00001
Central venous catheter 42 (93.3) 29 (52.7) 0.00001
Need for mechanical ventilation 41 (91.1) 28 (50.9) 0.00004
Severe sepsis, septic shock, multiorgan failure 23 (51.1) 5 (9.1) 0.00001
Non-S. maltophilia bloodstream infection 15 (33.3) 9 (16.3) 0.08
S. maltophilia bloodstream infection 12 (26.6) 13 (23.6) 0.9
Recent surgery 18 (40) 12 (21.8) 0.08
Polymicrobial infection 35 (77.7) 33 (60) 0.09
p-value < 0.05 was considered to be significant.
Data in boldface are significant.
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mortality also remained significant after their adjustment
for age and gender. Multivariate analysis with forward
stepwise logistic regression identified vasopressor ther-
apy (OR: 0.23, 95% CI: 0.08-0.65, p = 0.006) and central
venous catheter (OR: 0.15, 95% CI: 0.03-0.59, p = 0.007)
as independent determinants of mortality.
The count of WBC of infected patients ranged 0.05-37.7
Giga/L, median value was 11.2 Giga/L. Values of CRP and
PCT ranged 0.4-423 mg/L and 0.15-100 ng/mL, median
values were 86 mg/L and 1.6 ng/mL, respectively.
Other microorganisms were isolated together with S.
maltophilia from 68% of specimens. Numbers of these
isolates are shown in Table 3.
Discussion
Our study evaluated the antibiotic susceptibility of 160 S.
maltophilia isolates. In accordance with international
data, SXT was found to be the most effective anti-
microbial agent, so it is still the first recommended agent
for infections caused by S. maltophilia. Although resistancerates are increasing, in our study only four SXT non-
susceptible isolates (2.5%) were detected. This low
resistance rate is in concordance with European and
North-American data (2-10%) [1,2,14,15].
Fluoroquinolones represent alternative treatment op-
tions of S. maltophilia infections. It was shown that
fluoroquinolone and SXT monotherapy can achive equal
efficacy [16,17]. Unlike ciprofloxacin for which non-
susceptibility was found to be high, levofloxacin and
moxifloxacin were highly effective against the tested
isolates in vitro. Low MIC values of moxifloxacin should
be emphasized. This is in concordance with many other
studies [1,5,9,15]. Levofloxacin and moxifloxacin have
the additional advantage of disrupting S. maltophilia
biofilms and reducing biofilm mass, even in subinhibi-
tory concentrations [1,2,18]. Moreover, applying levo-
floxacin as inhalation therapy in respiratory tract
infections, the achievable concentration (50–100 mg/L)
is much higher than the highest MIC value (16 mg/L) in
our study. These effects increase the clinical value of
levofloxacin, especially in respiratory tract infections. It
Table 3 Other microorganisms isolated together with







Acinetobacter baumannii 7 1
Pseudomonas aeruginosa 24 7
other non-fermenting* 0 3
Enterobacteriaceae** 17 13
Gram positive
Coagulase negative Staphylococci 4 9
Staphylococcus aureus 8 7
Enterococcus sp. 10 8
Candida sp. 36 6
*Alcaligenes faecalis, Achromobacter xylosoxidans, Pseudomonas fluorescens
**Proteus mirabilis, Serratia marcescens, Escherichia coli, Klebsiella
pneumoniae, Klebsiella oxytoca, Enterobacter aerogenes, Enterobacter cloacae.
n: number of isolates.
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fluoroquinolones has been observed in S. maltophilia
[19]. The rate of developing resistance during monother-
apy was found 30% for fluoroquinolones and 20% for
SXT in a previous study [16]. Hence combination ther-
apy has been recommended in order to avoid emergence
of resistance and to provide synergism between anti-
microbial agents [1,6,16,20]. In the absence of clinical
trials it is still an ongoing debate whether treatment with
combination of antibiotics is superior to monotherapy.
Combination therapy can be suggested in severe invasive
infections and for immunocompromised patients until
further clinical evidences are available [6].
Susceptibility for doxycycline was investigated instead
of the often tested minocycline, since the latter is com-
mercially not available in Hungary. Using S. maltophilia
specific ECOFF, all the isolates appeared to be sensitive
to doxycyline. Since ECOFF and well-established clinical
breakpoints can differ significantly, it has to be assessed
wether this agent is a reliable therapeutic choice. In vitro
activity of tigecycline against S. maltophilia was deter-
mined as MIC50/MIC90 0.5/2 mg/L, which is in con-
cordance with international data [15]. Using EUCAST
non-specific breakpoints, 65% and 88% of our colonizer
and infective isolates were non-susceptible to tigecyc-
line, respectively. However, using EUCAST breakpoints
established for Enterobacteriaceae (S ≤ 1 mg/L, R >
2 mg/L) only 14% and 18%, while with breakpoints
established by USFDA for Enterobacteriaceae (S ≤
2 mg/L, R > 8 mg/L) only 10% and 4% of the isolates
were non-susceptible, respectively. Due to uncertain in-
terpretation the role of tigecycline as alternative choice
in the treatment of S. maltophilia infections is unclear.Clinical efficacy of tigecycline in S. maltophilia infec-
tions should be investigated. However, its synergism
with SXT and colistin in combination therapy was
reported [15,21].
Colistin was found to have weak in vitro activity against
our isolates, regardless of the testing method. Different
studies showed resistance rates of S. maltophilia to be 7-
100% for colistin, depending on the testing methods and
the breakpoints used [1,22]. Our results show that colistin
cannot be used in monotherapy in S. maltophilia infections;
however it can show synergism with certain agents [21].
Apart from SXT, it is still not decided which testing
method to use for different antimicrobial agents.
EUCAST declared that antibiotic susceptibility testing of
S. maltophilia is difficult since results are significantly
influenced by several conditions including incubation
temperature, culture medium or technique [4]. Suscepti-
bility testing of SXT and doxycyline however was proved
to be method independent and more reproducible than
that of other agents [11]. Apart from these two antibi-
otics, interpretation is recommended after prolonged,
48 h incubation [11]. In our study MIC values deter-
mined after 20 hours of incubation were accepted, while
CLSI method guideline was applied. Furthermore, sus-
ceptibility testing methods and breakpoints might be dif-
ferent depending on the site of infection: S. maltophilia
isolates from the respiratory tract of patients with CF or
other chronic lung diseases and isolates from blood-
stream infections should be tested and interpreted in a
different way [5]. Further studies are required to clarify
these questions.
The majority of S. maltophilia strains were isolated from
patients with polymicrobial infection or colonization. In-
terspecies interactions have an important role in bacterial
virulence: S. maltophilia can protect other bacteria from
antibiotics by degrading antimicrobial agents [23]. The
indirect pathogenicity of S. maltophilia due to its β-
lactamases was demonstrated [23]. While P. aeruginosa
was the most frequent co-pathogen in our study, it should
be considered that piperacillin-tazobactam, cefepime and
carbapenems can be useless anti-Pseudomonas agents in
an infection, where S. maltophilia expressing L1 and L2 β-
lactamases is also present. Stenotrophomonas maltophilia
as a co-colonizer might have a detrimental impact on P.
aeruginosa infections treated with aminoglycosides [6].
Quorum-sensing molecules produced by S. maltophilia
can also influence co-pathogen or co-colonizer bacteria
[1,24]. Moreover, the presence of S. maltophilia in a poly-
microbial community might lead to emergence of anti-
biotic resistance, since this species is carrying resistance
plasmids or transposons that facilitate the spread of resist-
ance integrons to other bacterial species [1]. Species
belonging to Enterobacteriaceae family were the second
most frequent co-pathogens in this study, including even
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Enterobacter cloacae strains [25]. Whether S. maltophilia
affected the resistance pattern of E. cloacae strains or vica
versa, is a further complex question. It is yet to be clarified
whether drug resistance determinants are transmitted be-
tween S. maltophilia and other bacteria within biofilms [5].
Other microorganisms causing infection together with S.
maltophilia can influence the clinical outcome as well [16].
Based on partial gyrB gene sequences, S. maltophilia
complex can be divided into distinct groups which differ
in antimicrobial resistance rates [26]. Further investiga-
tions are required to clarify whether there is a relation
between the protein mass spectra of S. maltophilia
group and antibiotic resistance.
Most infections caused by S. maltophilia were associ-
ated with severe morbidity and long-term, extensive ICU
treatment. Previously published mortality rates vary be-
tween 14-62% [16]. The high all-cause mortality rate
(45%) we observed can be connected to the serious under-
lying illnesses rather to S. maltophilia itself. However, the
strict attributable mortality rate (11%) was also high,
therefore clinical significance of S. maltophilia infections
must be considered particularly in patients admitted to
ICUs [27]. The fact that nearly 70% of infective isolates
were collected from lower respiratory tract samples has to
be considered as a limitation of our study.Conclusions
S. maltophilia is still a challenging multiresistant noso-
comial pathogen. Our results show that SXT is the most
potent antibiotic drug against S. maltophilia. Due to the
low frequency of moxifloxacin and levofloxacin resistance,
these agents can be used either in high dose monotherapy
or rather in combination with other antibiotics, concern-
ing the chance of rapid resistance development during
monotherapy. The establishment of clinical breakpoints
for agents other than SXT is strongly required in the near
future. The most reliable antibiotic susceptibility testing
method for alternative antibiotics should urgently be de-
clared. Clinicians have to consider that S. maltophilia as a
co-pathogen or co-colonizer in polymicrobial infections
can have negative impact on the success rate of antibiotic
treatment and clinical outcome.
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